Advanced Search
Submit Manuscript Volume 32, No 12, Dec 2022
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 32 Issue 12, December 2022: 1047-1067 |
Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors
Fan Zhang1,2,† , Qilin Zhang1,2,3,†,* , Jiajun Zhu1,2,† , Boyuan Yao1,2,3,† , Chi Ma4,† , Nidan Qiao1,2,3,† , Shiman He1,2,† , Zhao Ye1,2,3,† , Yunzhi Wang1,2 , Rui Han1,2,3 , Jinwen Feng1,2 , Yongfei Wang1,2,3 , Zhaoyu Qin1,2 , Zengyi Ma1,2,3 , Kai Li1,2 , Yichao Zhang1,2,3 , Sha Tian1,2 , Zhengyuan Chen1,2,3 , Subei Tan1,2 , Yue Wu3,5 , Peng Ran1,2 , Ye Wang1,2,3 , Chen Ding1,2,* , Yao Zhao1,2,3,6,7,8,9,*
1State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institute of Biomedical Sciences, Human Phenome Institute, Zhongshan Hospital, Fudan University, Shanghai, ChinaPituitary neuroendocrine tumor (PitNET) is one of the most common intracranial tumors. Due to its extensive tumor heterogeneity and the lack of high-quality tissues for biomarker discovery, the causative molecular mechanisms are far from being fully defined. Therefore, more studies are needed to improve the current clinicopathological classification system, and advanced treatment strategies such as targeted therapy and immunotherapy are yet to be explored. Here, we performed the largest integrative genomics, transcriptomics, proteomics, and phosphoproteomics analysis reported to date for a cohort of 200 PitNET patients. Genomics data indicate that GNAS
https://doi.org/10.1038/s41422-022-00736-5